Recent news coverage focuses on Alnylam's upcoming Q2 2026 earnings conference call, previews of revenue growth in transthyretin amyloidosis and rare diseases, and discussions of the company's drug pipeline potential and strategic positioning.

• Alnylam announced its Q2 2026 earnings conference call scheduled for July 30, 2026 [N1].
• Previews highlight potential revenue growth in transthyretin amyloidosis (TTR) and rare diseases segments for Q2 2026 [N3].
• Coverage discusses Alnylam's drug pipeline as a driver for long-term revenue growth and innovation leadership [N7].
• The company is reported to have net income in Q4 2025, reflecting operational profitability [N8].
• Wall Street anticipates earnings growth in upcoming reports, indicating market interest in Alnylam's financial performance [N4].

Alnylam's extensive pipeline with multiple late-stage programs, including next-generation nucresiran for ATTR amyloidosis and zilebesiran for hypertension, offers potential for expanding its therapeutic footprint. The company's 2030 strategy targets leadership in TTR amyloidosis and broad tissue expansion, supported by significant R&D investment. Collaborations with Roche and Regeneron provide access to additional resources and markets. Strong financial liquidity and recent net income generation support operational stability. Continued regulatory approvals and commercial launches could enhance revenue diversification and growth [S1][N7].

Risks include clinical trial failures or delays, as highlighted by industry phase 3 setbacks affecting biotech peers. Regulatory challenges or slower-than-anticipated market adoption of RNAi therapeutics could impact revenue growth. The company's reliance on collaborations introduces execution and dependency risks. Convertible debt and credit facility obligations require careful financial management. Competitive pressures from alternative therapeutic modalities and evolving standards of care may affect market share. The complexity of RNAi delivery and manufacturing could pose operational challenges [S1][N5].

Alnylam's competitive moat is based on its pioneering RNAi technology platform, which enables targeted gene silencing with potential to address diseases at the genetic root cause. The company has established a portfolio of six first-in-class RNAi therapeutics with regulatory approvals across multiple major markets. Its proprietary delivery technologies, including GalNAc conjugates and lipid nanoparticles, provide differentiated capabilities for tissue-specific targeting. Strategic collaborations with large pharmaceutical companies such as Novartis, Roche, and Regeneron enhance development and commercialization reach. The company's focus on genetically validated targets and early biomarkers supports efficient clinical development and regulatory pathways, reinforcing its innovation leadership and market position [S1].

• Clinical Development Risk: Late-stage clinical trials may fail to demonstrate efficacy or safety, impacting product approvals and pipeline progression.
• Regulatory and Market Access Risk: Regulatory delays or restrictions and challenges in patient access could limit commercial success of approved therapies.
• Collaborator Dependency Risk: Dependence on partners like Novartis, Roche, and Regeneron for development and commercialization introduces execution and strategic risks.
• Financial Risk: Convertible notes and credit facility obligations require prudent financial management to maintain liquidity and flexibility.
• Competitive Risk: Emerging therapies and alternative technologies may compete with RNAi therapeutics, affecting market penetration and pricing.

• Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company pioneering RNA interference (RNAi) therapeutics that silence disease-causing genes at the mRNA level [S1].
• The company has six approved RNAi-based medicines: AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Leqvio, and Qfitlia, targeting diseases including hereditary transthyretin-mediated amyloidosis (hATTR), acute hepatic porphyria, primary hyperoxaluria type 1, hypercholesterolemia, and hemophilia [S1].
• Alnylam's R&D strategy focuses on genetically validated targets with high unmet medical need, using GalNAc conjugate or lipid nanoparticle delivery for liver, and alternative conjugates for CNS and ocular delivery [S1].
• The company launched its Alnylam 2030 strategy aiming for global leadership in TTR amyloidosis, launching next-generation nucresiran, expanding to 10 tissue types and over 40 clinical programs, and targeting 25%+ compound annual revenue growth through 2030 [S1].
• Nucresiran is in Phase 3 trials for hATTR polyneuropathy and cardiomyopathy, with positive Phase 1 data showing durable TTR reductions [S1].
• Zilebesiran, targeting angiotensinogen for hypertension, is in a global Phase 3 cardiovascular outcomes trial (ZENITH) in collaboration with Roche [S1].
• Mivelsiran is in Phase 2 trials for cerebral amyloid angiopathy and planned for Alzheimer's disease, showing dose-dependent reductions of amyloid precursor protein beta in Phase 1 [S1].
• Cemdisiran, developed with Regeneron, is in Phase 3 trials for complement-mediated diseases including paroxysmal nocturnal hemoglobinuria and myasthenia gravis, with regulatory submission planned in 2026 [S1].
• The company issued $661.3 million of 0.00% Convertible Senior Notes due 2028 and repurchased a portion of 2027 Notes, maintaining capped call transactions to reduce dilution [S1].
• Alnylam has a $500 million revolving credit facility maturing in 2030, secured by substantially all assets and subject to customary covenants [S1].
• As of June 30, 2026, Alnylam reported $1.71 billion in cash and equivalents, $4.62 billion in current assets, $1.51 billion in current liabilities, a current ratio of 3.05, and a cash ratio of 1.13 [S2].
• Net income for Q2 2026 was $164.5 million with basic EPS of $1.23 and diluted EPS of $1.21 [S2].
• The company has more than 20 clinical programs including several late-stage developments [S1].
• Recent news highlights upcoming Q2 2026 earnings conference call and previews focusing on revenue growth in TTR and rare diseases [N1][N3].
• News coverage discusses Alnylam's drug pipeline potential for long-term revenue growth and strategic positioning in RNAi therapeutics [N7].
• Alnylam's financial results and net income reporting in Q4 2025 were covered in February 2026 [N8].